Is Hepatitis B entering the era of personalised medicine?

A.ThompsonA.Thompson
M.DouglasM.Douglas
BulletArticle
Infectious Diseases Liver disease & HCC
แชร์สิ่งนี้:
คัดลอกลิงก์
Is Hepatitis B entering the era of personalised medicine_thumbnail

New cure strategies for Hepatitis B are in development. Emerging data suggests a key role for biomarkers to identify subsets of people living with Hepatitis B who are most likely to respond to treatment. In this webinar, we discussed recent advances in Hepatitis B biomarker development, and how these tools can be used to personalise the management of people living with Hepatitis B.
 

แชร์สิ่งนี้:
คัดลอกลิงก์

เพิ่มเติมในหัวข้อเดียวกัน

PIVKA-II drives early detection of HCC in Vietnam

AMILI brings ‘precision gut microbiomics’ to Southeast Asia

หัวข้อแนะนำ

SequencingRED 2020Rare Diseases
สิ่งที่ต้องอ่านถัดไป
  • C-Suite Perspectives, Event Coverage, Healthcare Transformation, Management, RED 2024
Dr William Morice II’s visions and considerations for building a global diagnostics ecosystem
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
  • C-Suite Perspectives, Leaders In Conversation, Management
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top